Repurposing rupatadine as topical treatment against methicillin-resistant Staphylococcus aureus.

ABSTRACT: This study evaluates the potential of repurposed non-antibiotic drugs as possible treatments for methicillin-resistant Staphylococcus aureus (MRSA) skin infection, through a comprehensive approach combining in silico, in vitro, and in vivo methodologies. From 198 protein targets previously identified through multi-omics analysis, 10 essential, druggable, broad-spectrum targets were selected. Three promising non-antibiotic ligands (rupatadine, orlistat, and citric acid) were evaluated through minimum inhibitory concentration (MIC), minimum bactericidal concentration (MBC), molecular docking, cytotoxicity testing, and a murine model of MRSA skin infection. Rupatadine, orlistat, and citric acid showed MICs of 0.031 mg/mL, 1.5 mg/mL, and 2.5 mg/mL, respectively. Rupatadine demonstrated the mos

SUBMITTER: Farag A 

PROVIDER: S-EPMC12457276 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature